What the FDA labels say about taking them together
Dexlansoprazole and nelfinavir
Dexlansoprazole's FDA label of February 17, 2025 names nelfinavir in its drug interactions section; nelfinavir's label does not name dexlansoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The dexlansoprazole label: “The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. …”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.); the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON).
What does the dexlansoprazole label say about nelfinavir?
Dexlansoprazole label, drug interactionsAntiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (…) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance. … Intervention: Rilpivirine-containing products: Concomitant use with DEXILANT is contraindicated [see ]. See prescribing information. Atazanavir: See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with DEXILANT. See prescribing information for nelfinavir. …
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
What does the nelfinavir label say about dexlansoprazole?
Nelfinavir's label does not name dexlansoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Nelfinavir label, drug interactionsPROTON PUMP INHIBITORS Omeprazole ↓ nelfinavir Omeprazole decreases the plasma concentrations of nelfinavir.
Nelfinavir label, drug interactionsPROTON PUMP INHIBITORS Omeprazole ↓ nelfinavir Omeprazole decreases the plasma concentrations of nelfinavir. Concomitant use of proton pump inhibitors and VIRACEPT may lead to a loss of virologic response and development of resistance.
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexlansoprazole | Nelfinavir | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $3.71 per capsule 60 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once